英伟达与艾伯维支持的AI制药公司Iambic首日上市较发行价涨超10%

Iambic Therapeutics ( IAM ), a life sciences company backed by Nvidia ( NVDA ) and AbbVie ( ABBV ), among others, rose more than 10% above its initial public offering price on Thursday in its first trading session as a listed firm. Iambic ( IAM ) shares opened at $16.15 at about 12 pm ET, roughly unchanged from the IPO price, then quickly added about 11% to reach $17.95 about an hour later, implying a valuation of roughly $876M. Late Wednesday, the San Diego-based AI-driven drug discovery firm priced the offering of roughly 9.4M shares at $16.00, targeting about $150M in gross proceeds. A 30-day option was available for underwriters to purchase up to ~1.4M shares additionally at the IPO price adjusted for underwriting discounts and commissions. Iambic ( IAM ) expects the offering to generate about $135M in net proceeds, which it intends to use, among other things, to advance its lead asset IAM1363. The oral tyrosine kinase inhibitor is currently undergoing a Phase 1/1b clinical trial for advanced HER2-altered solid tumors ahead of a potentially registrational study expected to begin next year. Since its inception in 2019, the company has raised approximately $461.8M from technology- and healthcare-focused investors, including Nvidia ( NVDA ). ARK Investment Management, one of its existing investors, and Duquesne Family Office LLC had agreed to buy $60M worth of stock at the offering price, a filing indicated last week. In September, Iambic ( IAM ) partnered with AbbVie ( ABBV ) to accelerate AI-led drug discovery in the areas of immunology, neuroscience, and oncology as part of a multi-year collaboration.